X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6622) 6622
Book Review (1508) 1508
Publication (638) 638
Newspaper Article (390) 390
Newsletter (94) 94
Magazine Article (82) 82
Conference Proceeding (63) 63
Book / eBook (58) 58
Government Document (42) 42
Book Chapter (38) 38
Trade Publication Article (31) 31
Web Resource (26) 26
Transcript (20) 20
Report (11) 11
Dissertation (7) 7
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5051) 5051
humans (4763) 4763
female (2889) 2889
oncology (2666) 2666
male (2372) 2372
middle aged (2074) 2074
chemotherapy (1933) 1933
cancer (1817) 1817
adult (1785) 1785
aged (1702) 1702
maintenance (1603) 1603
maintenance therapy (1358) 1358
maintenance chemotherapy (1330) 1330
treatment outcome (1231) 1231
hematology (1120) 1120
antineoplastic combined chemotherapy protocols - therapeutic use (1033) 1033
care and treatment (983) 983
health maintenance organizations (827) 827
therapy (803) 803
analysis (733) 733
research (675) 675
survival (650) 650
aged, 80 and over (648) 648
disease-free survival (605) 605
prognosis (583) 583
adolescent (579) 579
patients (564) 564
antineoplastic agents - therapeutic use (540) 540
animals (522) 522
retrospective studies (517) 517
health aspects (508) 508
medicine & public health (483) 483
trial (465) 465
drug therapy (457) 457
clinical trials (454) 454
remission induction (452) 452
young adult (444) 444
cancer therapies (438) 438
risk factors (435) 435
breast cancer (425) 425
pharmacology & pharmacy (422) 422
stem cells (414) 414
transplantation (407) 407
abridged index medicus (405) 405
hematology, oncology and palliative medicine (405) 405
ovarian cancer (398) 398
double-blind (394) 394
child (389) 389
multiple myeloma (388) 388
tumors (388) 388
quality of life (385) 385
follow-up studies (384) 384
antineoplastic combined chemotherapy protocols - adverse effects (369) 369
open-label (366) 366
survival analysis (362) 362
lung neoplasms - drug therapy (358) 358
neoplasm staging (356) 356
recurrence (355) 355
maintenance chemotherapy - methods (347) 347
stem-cell transplantation (343) 343
medicine, general & internal (337) 337
rituximab (337) 337
article (336) 336
medical research (335) 335
bevacizumab (328) 328
studies (328) 328
prospective studies (320) 320
drug administration schedule (316) 316
immunotherapy (316) 316
time factors (314) 314
induction chemotherapy (313) 313
survival rate (311) 311
metastasis (299) 299
lung cancer (298) 298
combined modality therapy (293) 293
leukemia (292) 292
mutation (291) 291
multiple myeloma - drug therapy (280) 280
expression (275) 275
diagnosis (273) 273
carcinoma, non-small-cell lung - drug therapy (272) 272
risk (271) 271
quality-of-life (270) 270
randomized-trial (270) 270
medicine (269) 269
randomized controlled trials as topic (264) 264
phase-iii trial (263) 263
immunology (260) 260
surgery (256) 256
relapse (255) 255
genetic aspects (249) 249
carcinoma (247) 247
child, preschool (246) 246
children (246) 246
breast-cancer (244) 244
cyclophosphamide (242) 242
gastroenterology & hepatology (242) 242
kaplan-meier estimate (242) 242
management (242) 242
oncology, experimental (240) 240
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (50) 50
Collection Dvlpm't (Acquisitions) - Closed Orders (5) 5
Online Resources - Online (3) 3
UTL at Downsview - May be requested (3) 3
UofT at Mississauga - Stacks (3) 3
Engineering & Comp. Sci. - Stacks (2) 2
Robarts - Stacks (2) 2
St. Michael's College (John M. Kelly) - 2nd Floor (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Criminology - Stacks (1) 1
Law (Bora Laskin) - Stacks (1) 1
OISE - Stacks (1) 1
Scarborough Hospital - General (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7174) 7174
French (86) 86
German (42) 42
Japanese (32) 32
Spanish (22) 22
Russian (14) 14
Chinese (12) 12
Polish (9) 9
Portuguese (7) 7
Italian (5) 5
Korean (5) 5
Czech (4) 4
Hungarian (2) 2
Arabic (1) 1
Croatian (1) 1
Serbian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Urology, ISSN 0302-2838, 2007, Volume 52, Issue 4, pp. 1123 - 1130
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2012, Volume 367, Issue 17, pp. 1616 - 1625
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 12/2015, Volume 62, Issue 12, pp. 2132 - 2139
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 08/2014, Volume 9, Issue 8, pp. 1180 - 1186
Over the past decade, well tolerated second-line therapies for advanced non–small-cell lung cancer have been approved including erlotinib and pemetrexed in... 
Second line | Non–small-cell lung cancer | Erlotinib | Pemetrexed | Docetaxel | Predictors | Non-small-cell lung cancer | GEFITINIB | 1ST-LINE CHEMOTHERAPY | RANDOMIZED-TRIAL | PLUS CARBOPLATIN | MAINTENANCE THERAPY | PHASE-III TRIAL | SUPPORTIVE CARE | CISPLATIN | ONCOLOGY | RESPIRATORY SYSTEM | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Lung Neoplasms - ethnology | Age Factors | Guanine - analogs & derivatives | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vinblastine - administration & dosage | Vinblastine - analogs & derivatives | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Retrospective Studies | Drug Therapy - trends | Carcinoma, Non-Small-Cell Lung - pathology | Survival Rate - trends | Deoxycytidine - administration & dosage | Carcinoma, Non-Small-Cell Lung - ethnology | British Columbia | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sex Factors | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Platinum Compounds - administration & dosage | Asian Continental Ancestry Group - statistics & numerical data | Deoxycytidine - analogs & derivatives | Guanine - administration & dosage | Index Medicus
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9759, pp. 42 - 51
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2016, Volume 34, Issue 25, pp. 2969 - 2979
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 874 - 885
Summary Background Relapsed multiple myeloma has no standard treatment, and the role of autologous stem-cell transplantation (ASCT) has not been fully defined.... 
Hematology, Oncology and Palliative Medicine | MAINTENANCE | SUPERIORITY | BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE | IMPACT | METAANALYSIS | ONCOLOGY | CLINICAL-TRIALS | LENALIDOMIDE | SALVAGE THERAPY | INDUCTION | MARROW TRANSPLANTATION | Recurrence | Cyclophosphamide - administration & dosage | Peripheral Nervous System Diseases - chemically induced | Consolidation Chemotherapy - methods | Humans | Middle Aged | Pyrazines - administration & dosage | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Antineoplastic Agents, Alkylating - administration & dosage | Cyclophosphamide - adverse effects | Multiple Myeloma - therapy | Time Factors | Adult | Female | Boronic Acids - administration & dosage | Neutropenia - chemically induced | Doxorubicin - administration & dosage | Bortezomib | Dexamethasone - administration & dosage | Proportional Hazards Models | Thrombocytopenia - chemically induced | Disease Progression | Induction Chemotherapy - adverse effects | Retreatment | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged | Multiple Myeloma - genetics | Stem Cell Transplantation - adverse effects | Care and treatment | Relapse | Multiple myeloma | Clinical trials | Transplantation | Diseases | Cyclophosphamide | Chemotherapy | Hospitals | Stem cells | Dosage and administration | Product development | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 87 - 97
Summary Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade... 
Hematology, Oncology and Palliative Medicine | LIPOSOMAL DOXORUBICIN | MULTICENTER | INHIBITION | SOLID TUMORS | CISPLATIN | ONCOLOGY | POLYMERASE | OPEN-LABEL | COMBINATION | CARCINOMA | MAINTENANCE THERAPY | Piperazines - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Enzyme Inhibitors - adverse effects | Neoplasms, Cystic, Mucinous, and Serous - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Neoplasms, Cystic, Mucinous, and Serous - enzymology | Treatment Outcome | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | BRCA1 Protein - genetics | Disease-Free Survival | Administration, Intravenous | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | BRCA2 Protein - genetics | Neoplasms, Cystic, Mucinous, and Serous - mortality | Phthalazines - adverse effects | Relapse | Chemotherapy | Hospitals | Gene mutations | Sugars | Diseases | Cancer | Monosaccharides | Ovarian cancer | Index Medicus
Journal Article
Lung Cancer, ISSN 0169-5002, 2017, Volume 108, pp. 232 - 237
Journal Article